PISD: A Protein Regulating Pain Signaling in The Brain (G23761)

Target Name: PISD

NCBI ID: G23761

PISD

PISD: A Protein Regulating Pain Signaling in The Brain

PISD (PISD variant 1) is a protein that is expressed in the brain and is known for its role in the regulation of pain signaling. It is a potential drug target and biomarker for various neurological and psychiatric disorders.

PISD is a member of the PISD family, which includes several related proteins that are involved in the regulation of pain signaling. The PISD proteins are characterized by a unique N-terminal region that consists of a short amino acid sequence and a long non-coding RNA (ncRNA) that is expressed in the brain.

The N-terminus of PISD contains a region that is similar to the TATA-repeat domain, which is a common element in the binding of transcription factors to DNA. This domain is known to play a role in the regulation of gene expression and is thought to be involved in the regulation of pain signaling.

PISD is also characterized by a unique C-terminus that is composed of a long terminal extension and a short cytoplasmic tail. The cytoplasmic tail of PISD is thought to be involved in the regulation of the stability and localization of the protein in the brain.

PISD is expressed in a variety of tissues and cells, including neurons, glial cells, and microglia. It is also highly expressed in the brain, where it is thought to play a role in the regulation of pain signaling.

Studies have suggested that PISD is involved in the regulation of pain signaling in the brain. For example, PISD has been shown to be involved in the regulation of pain perception and neuroinflammation. It has also been shown to play a role in the regulation of neurotransmitter signaling, including the regulation of dopamine release.

In addition to its potential role in pain signaling, PISD is also thought to be involved in the regulation of other processes in the brain. For example, it has been shown to play a role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. It has also been shown to play a role in the regulation of neurogenesis, which is the process by which new neurons are generated in the brain.

Given its potential role in the regulation of pain signaling and other processes in the brain, PISD is an attractive drug target for the development of new treatments for various neurological and psychiatric disorders. Studies are currently being conducted to determine the efficacy of PISD-targeted therapies in animal models of pain and psychiatric disorders.

In conclusion, PISD is a protein that is expressed in the brain and is known for its role in the regulation of pain signaling. It is a potential drug target and biomarker for various neurological and psychiatric disorders. Further studies are needed to determine its full role in the regulation of pain and other processes in the brain.

Protein Name: Phosphatidylserine Decarboxylase

Functions: Catalyzes the formation of phosphatidylethanolamine (PtdEtn) from phosphatidylserine (PtdSer) (PubMed:30488656, PubMed:30858161). Plays a central role in phospholipid metabolism and in the interorganelle trafficking of phosphatidylserine. May be involved in lipid droplet biogenesis at the endoplasmic reticulum membrane (By similarity)

The "PISD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PISD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets